DORAL, Florida, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces its agreement with Groupe Opmedic Inc. and its Procrea Fertility Laboratories to provide the laboratory services for the detection of sexually transmitted infections (STIs) in women using Hygee™.
ETST’s Hygee™ self-sampling kit mimics a standard feminine hygiene panty liner. When worn for four hours, the subtle device collects and stores a cervical cell sample, which the woman can mail to the Procrea Fertility lab for anonymous and discreet testing for STIs.
“We are extremely happy to be working with Earth Science Tech on its Hygee™ project,” said Dr Pierre St-Michel, president of Groupe Opmedic. “This new sample collection technology will allow women who lack access to health care to take their testing into their own hands.”
ETST has already proven the Hygee™ device’s ability to collect cell samples to detect chlamydia, and is working to validate similar results for gonorrhea. Untreated chlamydia infections may have serious effects on the female reproductive system, and on the fetus a pregnant woman is carrying. For this reason, women who are pregnant should be tested for chlamydia infection. Hygee™ will make this process easier, more accessible, and more cost-efficient while protecting the privacy of the woman.
In the near future, ETST will add testing for other STIs and non-STI infections that will make the device ever more useful.
Procrea Fertility offers an advanced range of laboratory testing of cervical cells, including tests for human papillomavirus (HPV), chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). As stated above, the cervical cell samples collected using Hygee™ are only certified for CT testing, with NG certification to follow shortly.
“We are excited to be working with partner that has the same vision as we do,” said Dr. Michel Aubé, CEO and CSO of ETST. “We are concerned for the health of all women and the babies they carry when pregnant. The CT test is so essential for infant’s health that the World Health Organization (WHO) encourages all sexually active women between the ages of 15 and 25 to be tested once a year.”
As they become available, ETST plans to share further updates on the Hygee medical device.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science Tech poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.